Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $12.40

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus rating of “Moderate Buy” by the five analysts that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $12.40.

Several equities research analysts recently issued reports on INO shares. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of Inovio Pharmaceuticals in a research note on Friday, January 10th. Royal Bank of Canada cut their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research report on Friday, November 15th. Oppenheimer decreased their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. Finally, HC Wainwright cut their price objective on shares of Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating for the company in a research report on Monday, January 13th.

Inovio Pharmaceuticals Trading Down 2.0 %

Inovio Pharmaceuticals stock opened at $1.92 on Tuesday. The company has a market capitalization of $50.11 million, a price-to-earnings ratio of -0.91 and a beta of 0.89. The stock’s 50 day moving average is $2.33 and its 200-day moving average is $4.95. Inovio Pharmaceuticals has a 12 month low of $1.74 and a 12 month high of $14.75.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in INO. BNP Paribas Financial Markets grew its stake in Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 3,630 shares during the period. SG Americas Securities LLC acquired a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at $71,000. The Manufacturers Life Insurance Company bought a new stake in Inovio Pharmaceuticals during the 2nd quarter valued at $82,000. MetLife Investment Management LLC raised its holdings in Inovio Pharmaceuticals by 129.1% during the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 8,546 shares during the last quarter. Finally, Atom Investors LP bought a new position in shares of Inovio Pharmaceuticals in the third quarter valued at $103,000. 26.79% of the stock is owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.